bioAffinity CyPath Lung unit sales jump 146% in Q1 2026

Reuters04-01

bioAffinity CyPath Lung unit sales jump 146% in Q1 2026

bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.
US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.
Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.
Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.
CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604010800BIZWIRE_USPR_____20260401_BW043688) on April 01, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624513351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624513351","market":"fut","top_or_hot":-1,"title":"bioAffinity CyPath Lung unit sales jump 146% in Q1 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      bioAffinity CyPath Lung unit sales jump 146% in Q1 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.\n        </li>\n<li>\n          US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.\n        </li>\n<li>\n          Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.\n        </li>\n<li>\n          Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.\n        </li>\n<li>\n          CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604010800BIZWIRE_USPR_____20260401_BW043688) on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>bioAffinity CyPath Lung unit sales jump 146% in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nbioAffinity CyPath Lung unit sales jump 146% in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-01 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      bioAffinity CyPath Lung unit sales jump 146% in Q1 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.\n        </li>\n<li>\n          US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.\n        </li>\n<li>\n          Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.\n        </li>\n<li>\n          Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.\n        </li>\n<li>\n          CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604010800BIZWIRE_USPR_____20260401_BW043688) on April 01, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIAF","symbol_name":"bioAffinity Technologies, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5nzSmF:1","article_id":"2624513351","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624513351","pubTimestamp":1775044964,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIAF":"bioAffinity Technologies, Inc.","BK4139":"生物科技"},"translate_title":"2026年第一季度bioAffinity CyPath肺部单位销售额增长146%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIAF":0.9},"content_text":"bioAffinity CyPath Lung unit sales jump 146% in Q1 2026\n    \n\n\n          bioAffinity posted 146% year-over-year growth in Q1 2026 unit sales for CyPath Lung, based on preliminary unaudited data.\n        \n\n          US addressable market for pulmonary nodule management and lung cancer survivor surveillance was estimated at USD 3.58 billion.\n        \n\n          Projected US indeterminate pulmonary nodule volume was forecast to rise 62% to 4.7 million by 2030 from 2.9 million in 2025.\n        \n\n          Estimated lung cancer survivor population was projected to increase to more than 871,000 by 2030 from 680,000.\n        \n\n          CyPath Lung revenue rose 87% in 2025; test units sold increased 99% versus 2024.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604010800BIZWIRE_USPR_____20260401_BW043688) on April 01, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624513351","isCrawlerRequest":true}